{"id":"W2590061441","doi":"10.1200/jco.2016.34.2_suppl.200","title":"Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Leuprorelin; Prostate cancer; Clinical endpoint; Urology; Gonadotropin-releasing hormone antagonist; Internal medicine; Interim analysis; Hormone antagonist; Prostate-specific antigen; Testosterone (patch); Prostate; Pharmacokinetics; Antagonist; Gastroenterology; Cancer; Randomized controlled trial; Gonadotropin-releasing hormone; Hormone; Luteinizing hormone; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002771376,0.0001718757,0.002077818,0.0004075906,0.0000374617,0.000008774959,0.0002222369,0.0002758808,0.0008334969],"category_scores_gemma":[0.002066863,0.00009191028,0.0005732307,0.0004137665,0.0003544929,0.0002323019,0.00009377106,0.000598174,0.000004306396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003976637,"about_ca_system_score_gemma":0.002011295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003650632,"about_ca_topic_score_gemma":0.001742138,"domain_scores_codex":[0.9947239,0.0007054908,0.003407832,0.0003363881,0.0004943779,0.0003320766],"domain_scores_gemma":[0.9952548,0.001190106,0.002126423,0.0002814774,0.0006797945,0.0004673808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6143283,0.0185136,0.0984608,0.00001453542,0.002038322,0.000524691,0.0005763507,0.000002628374,0.001158429,0.000002341843,0.001947492,0.2624325],"study_design_scores_gemma":[0.6798236,0.1487157,0.1377724,0.0002647409,0.001532091,0.00000617146,0.0001269025,0.00009486132,0.001603092,0.0002065971,0.02969211,0.0001617381],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932564,0.0001996832,0.00001016645,0.004066418,0.0008945885,0.0004867294,0.0006264169,0.000005019465,0.0004545221],"genre_scores_gemma":[0.9961113,0.001382856,0.0003173747,0.0002965095,0.000684278,0.0000140683,0.0000752307,0.00001562181,0.001102816],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2622708,"threshold_uncertainty_score":0.9126207,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1804699472172132,"score_gpt":0.5432057560749756,"score_spread":0.3627358088577624,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}